@article{0c02180fcd134073be817542b6ee62a6,
title = "A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)",
author = "S. Bellone and Roque, {D. M.} and Siegel, {E. R.} and N. Buza and P. Hui and E. Bonazzoli and A. Guglielmi and L. Zammataro and N. Nagarkatti and S. Zaidi and J. Lee and Silasi, {D. A.} and Huang, {G. S.} and V. Andikyan and S. Damast and M. Clark and M. Azodi and Schwartz, {P. E.} and J. Tymon-Rosario and J. Harold and D. Mauricio and B. Zeybek and G. Menderes and G. Altwerger and E. Ratner and Alexandrov, {L. B.} and A. Iwasaki and Y. Kong and E. Song and W. Dong and J. Elvin and J. Choi and Santin, {A. D.}",
note = "Funding Information: This work was supported in part by grants from the National Institutes of Health (NIH) [grant number U01 CA176067-01 ], the Tina Brozman Foundation , the Guido Berlucchi Foundation , and Gilead Sciences Inc . (no grant numbers), Foster City, CA to AS. This investigation was also supported by NIH Research Grant [grant number CA-16359 ] from the National Cancer Institute and Stand-Up-To-Cancer (SU2C) convergence grant 2.0 to AS. Funding Information: We would like to thank Merck USA for its industry support. This work was supported in part by grants from the National Institutes of Health (NIH) [grant number U01 CA176067-01], the Tina Brozman Foundation, the Guido Berlucchi Foundation, and Gilead Sciences Inc. (no grant numbers), Foster City, CA to AS. This investigation was also supported by NIH Research Grant [grant number CA-16359] from the National Cancer Institute and Stand-Up-To-Cancer (SU2C) convergence grant 2.0 to AS. The authors have declared no conflicts of interest.",
year = "2021",
month = aug,
doi = "10.1016/j.annonc.2021.04.013",
language = "English",
volume = "32",
pages = "1045--1046",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "8",
}
